TON - March 2013, Vol 6, No 2

OnPART can predict 6 common side effects of dose-dense doxorubicin plus cyclophosphamide plus paclitaxel chemotherapy in patients with breast cancer with a high degree of accuracy, according to the results of a study presented at the CTRC-AACR San Antonio Breast Cancer Symposium. Read More ›

The antidepressant venlafaxine is often prescribed to patients with breast cancer who are taking tamoxifen, to help reduce the side effect of hot flashes. But according to research presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium, venlafaxine may reduce the effectiveness of the drug. Read More ›

Lynch syndrome is a hereditary disorder caused by a mutation in a mismatch repair gene in which affected individuals have an increased risk of developing colorectal cancer, endometrial cancer, and various other types of aggressive cancers. Read More ›

As we know, the American healthcare system is going through exorbitant changes, changes that will affect all providers and all stakeholders in the cancer care ecosystem. Read More ›

Peripheral artery occlusive disease (PAOD) may be an adverse effect of nilotinib treatment in patients with chronic-phase chronic myeloid leukemia (CML), according to a study presented at the 54th Annual Meeting of the American Society of Hematology. Read More ›

To prevent bleeding related to stem cell transplant or intense induction and conditioning regimens, prophylactic platelet infusion remains the standard of care, according to a study that compared outcomes for patients who received prophylaxis versus those who did not. Read More ›

Total parenteral nutrition (TPN) continues to be inappropriately used at the end of life in cancer patients, according to a review of home-based TPN reported by researchers from Moffitt Cancer Center in Tampa, Florida, at the 2013 Gastrointestinal Cancers Symposium. Read More ›

While branded and generic enoxaparin share many traditional characteristics of low-molecular-weight heparins (LMWHs), they differ in several parameters that are relevant to an antithrombotic effect, according to researchers from Loyola University Medical Center, Maywood, Illinois, who presented their findings at the 54th Annual Meeting of the American Society of Hematology. Read More ›

Adverse effects (AEs) with regorafenib tend to occur early—during the first treatment cycle—and then quickly taper off. Read More ›

At the ASH plenary session, investigators showed that acute promyelocytic leukemia (APL), traditionally one of the deadliest hematologic malignancies, can be treated without chemotherapy. Read More ›

Page 1 of 2

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: